Nabi Biopharmaceuticals begins human testing of novel vaccine.(Brief Article)

2002 JUL 24 - (NewsRx.com & NewsRx.net) -- Nabi Biopharmaceuticals (NABI) has initiated NicVAX (nicotine conjugate vaccine) phase I testing in humans. NicVAX is a proprietary and novel investigational vaccine designed to help the body develop antibodies that bind to nicotine and block it from reaching the brain. If shown to be safe and effective in subsequent clinical trials, NicVAX may help millions of people worldwide kick their addiction to cigarettes and tobacco products.

"NicVAX is an entirely new approach to fighting and preventing nicotine addiction," said David J. Gury, Nabi Biopharmaceuticals chairman, president and chief executive officer.

Of the 48 million adult U.S. smokers, about 70%, or nearly 34 million people, have made at least one attempt to stop, yet only 1.2 million quit permanently, according to the U.S. Centers for Disease Control and Prevention.

"When a person smokes, nicotine enters the body and goes straight to the brain, where it generates positive sensations, such as pleasure and relaxation," said Robert Naso, PhD, Nabi Biopharmaceuticals senior vice president of quality, regulatory and product development. "However, the body does not develop antibodies against nicotine, no matter how much or for how long a person smokes. Based on earlier animal studies, NicVAX is a technology that enables the body to develop antibodies to nicotine. We believe that these antibodies, acting much like a sponge, will soak up the ...